Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients

Hypertension Research

Volumn 26, Issue 11, 2003, Pages 881-886

  Yu, Huimin ^a   Zhang, Yuqing ^a   Liu, Guozhang ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Angiotensin converting enzyme; Angiotensin converting enzyme inhibition; Essential hypertension; Genotype; Polymorphism

Indexed keywords

BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; GENOMIC DNA; IMIDAPRIL; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FEMALE; GENE DELETION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; POLYMERASE CHAIN REACTION; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

AGED; ALLELES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; DATA INTERPRETATION, STATISTICAL; DNA; DNA PRIMERS; DOUBLE-BLIND METHOD; FEMALE; GENE FREQUENCY; HUMANS; HYPERTENSION; IMIDAZOLES; IMIDAZOLIDINES; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEX CHARACTERISTICS;

EID: 0344237243     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.26.881     Document Type: Article

References (45)

1. Bidiville J, Nussberger J, Waeber G, et al: Individual responses to converting enzyme inhibitors and calcium antagonists. Hypertension 1988; 11: 166-173.
2. Motulsky A: Drug reactions, enzymes and biochemical genetics. J Am Med Assoc 1957; 165: 835-837.
3. Hickman D, Risch A, Buckie V, et al: Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J 1994; 297: 441-445.
4. Daly A, Brockmoller J, Broly F, et al: Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193-201.
5. Grossma M, Littrell J, Weinstein R, et al: Identification of the possible molecular basis for inherited differences in human catechol-o-methyltransferase. Neurosci Soc 1992; 18: 70.
6. Weinshilboum R, Ottemess D, Szumlanski C, et al: Methylation pharmacogenetics: catechol-o-methyltransferase, thiopurine methyltransferase, and histamine n-methyltransferase. Annu Rev Pharmacol Toxicol 1999; 39: 19-25.
7. Tamaki S, Nakamura Y, Tsujita Y, et al: Polymorphism of the angiotensin converting enzyme gene and blood pressure in a Japanese general population (the Shigaraki Study). Hypertens Res 2002; 25: 843-848.
8. Schmidt S, Beige J, Walla-Friedel M, et al: A polymorphism in the gene for the angiotensin II type 1 receptor is not associated with hypertension. J Hypertens 1997; 15: 1385-1388.
9. Ono K, Mannami T, Baba S, Yasui N, et al: Lack of association between angiotensin II type 1 receptor gene polymorphism and hypertension in Japanese. Hypertens Res 2003; 26: 131-134
10. Kikuya M, Sugimoto K, Katsuya T, et al: A/C1166 gene polymorphism of the angiotensin II type 1 receptor (AT1) and ambulatory blood pressure: the Ohasama Study. Hypertens Res 2003; 26: 141-145.
11. Caulfield M, Lavender P, Newell-Price J, et al: Angiotensinogen in human essential hypertension. Hypertension 1996; 28: 1123-1125.
12. Formage M, Amos CL, Kardia S, et al: Variation in the region of the angiotensin-convering enzyme gene influences interindividual difference in blood pressure levels in young white males. Criculation 1998; 97: 1773-1779.
13. Kainulainen K, Perola M, Terwilliger J, et al: Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension. Hypertension 1999; 33: 844-849.
14. Katsuya T, Iwashima Y, Sugimoto K, et al: Effects of anti-hypertensive drugs and gene variants in the renin-angiotensin system. Hypertens Res 2001; 24: 463-467.
15. Moriyama T, Kitamura H, Ochi S, et al: Association of angiotensin I-converting enzyme gene polymorphism with susceptibillity to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria. J Am Soc Nephrol 1995; 6: 1674-1678.
16. Hingorani AD, Jia H, Stevens PA, et al: Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995; 13: 1602-1609.
17. Sasaki M, Oki T, Luchi A, et al: Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens 1996; 14: 1403-1408.
18. Dudley C, Keavney B, Casadei B, et al: Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of the renin-angiotensin system genes. J Hypertens 1996; 14: 259-262.
19. Nakano Y, Oshima T, Watanabe M, et al: Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension. Am J Hypertens 1997; 10: 1064-1068.
20. Ueda S, Meredith PA, Morton JJ, et al: ACE (I/D) genotype as a predictor of the magnitude and duration of the response an ACE inhibitor drug (enalaprilat) in humans. Criculation 1998; 98: 2148-2153.
21. Mondorf U, Russ A, Wiesemann A, et al: Contribution of ACE gene polymorphism and angiotensinogen gene polymorphism to blood pressure reduction in essential hypertension. Am J Hypertens 1998; 11: 174-183.
22. Miller JA, Thai K, Scholey JW: Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999; 56: 2173-2180.
23. George A, Stavroulakis, Thomas K, et al: Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000; 14: 427-432.
24. Kurland L, Melhus H, Karlsson J, et al: Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19: 1783-1787.
25. Katsuya T, Iwashima Y, Sugimoto K, et al: Effects of anti-hypertensive drugs and gene variants in the renin-angiotensin system. Hypertens Res 2001; 24: 463-467.
26. Schwartz GL, Turner ST, Chapman AB, et al: Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002; 62: 1718-1723.
27. Tiret L, Rigat B, Visviks S, et al: Evidence from combined segregation and linkage analysis that a variant of the ACE gene controls plasma levels. Am J Hum Genet 1992; 1: 197-205.
28. Yoshida H, Mitarai T, Kawamura T, et al: Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995; 96: 2162-2169.
29. Todd G, Chadwick I, Higgins K, et al: Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects. Br J Clin Pharmacol 1995; 39: 131-134.
30. Dieguez-Lucena J, Aranda-Lara P, Ruiz-Galdon M, et al: Angiotensin I-converting enzyme genotypes and angiotensin II receptor: response to therapy. Hypertension 1996; 28: 98-103.
31. Mizuiri S, Hemmi H, Inoue A, et al: Renal hemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism. Nephron 1997; 75: 310-314.
32. Zee R, Rao V, Paster R, et al: Three candidate genes and angiotensin-converting enzyme inhibitor-related cough. Hypertension 1998; 31: 925-928.
33. Haas M, Yilmaz N, Schmidt A, et al: Angiotensin converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Kidney Blood Press Res 1998; 21: 66-69.
34. van der Kleij F, Schmidt A, Navis G, et al: Angiotensin converting enzyme gene insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int 1998; 53: S23-S26.
35. Cannella G, Paoletti E, Barocci S, et al: Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy. Kidney Int 1998; 54: 618-626.
36. Henrion D, Amant C, Benessiano J, et al: Angiotensin II type 1 receptor gene polymorphism is associated with an increased vascular reactivity in the human mammary artery in vivo. J Vasc Res 1998; 35: 356-362.
37. Bloem L, Manatunga A, Tewksbury D, et al: The serum angiotensin concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest 1995; 95: 948-953.
38. White P: Inherited forms of mineralocorticoid hypertension. Hypertension 1996; 32: 927-936.
39. Inoue I, Nakajima T, Williams C, et al: A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997; 99: 1786-1797.
40. Juillerat L, Nussberger J, Menard J, et al: Determinants of angiotensin II generation during ACE inhibition. Hypertension 1990; 16: 564-572.
41. Rigat B, Hubert C, Alhenc-Gelas F, et al: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
42. McKenzie CA, Julier C, Forrester T, et al: Segregation and linkage analysis of serum angiotensin I-converting enzyme levels: evidence for two quantitative-treat loci. Am J Hum Genet 1995; 57: 1426-1435.
43. Renaland R, Hanni A, Andersson PE, et al: Skeletal muscle angiotensin-converting enzyme and its relationship to blood pressure in primary hypertension and healthy elderly men. Blood Press 1999; 8: 16-22.
44. Biollaz J, Brunner HR, Gavras I, et al: Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982; 4: 966-972.
45. Rousseau MF, Konstam MA, Benedict CR, et al: Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994; 73: 488-493.